SOURCE: Amarin Corp. Plc

Amarin Corp. Plc

January 05, 2015 07:00 ET

Amarin to Present at the 33rd Annual J.P. Morgan Healthcare Conference

BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - January 05, 2015) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, at 11:00 a.m. PT.

A live audio webcast of the presentation will be available at:

http://jpmorgan.metameetings.com/confbook/healthcare15/directlink?p=17265

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to an ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

Contact Information